Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Mrs. ANJALI**		
AGE/ GENDER	: 35 YRS/FEMALE	**PATIENT ID**	: 1578008
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408120032**
REFERRED BY	:	**REGISTRATION DATE**	: 12/Aug/2024 11:44 AM
BARCODE NO.	: 01514938	**COLLECTION DATE**	: 12/Aug/2024 11:46AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 14/Aug/2024 04:18PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

ENDOCRINOLOGY

DUAL MARKER MATERNAL SCREENING

DUAL MARKER TEST

PATEINT SPECIFICATIONS

DATE OF BIRTH	22-08-1989		
MATERNAL AGE	35	YEARS	
WEIGHT	56.3	Kg	
ETHNIC ORIGIN	ASIAN		ASIAN
H/O IVF	ABSENT		
H/O SMOKING	ABSENT		
H/O INSULIN DEPENDANT DIABETES	ABSENT		
H/O TRISOMY 21 SCREENING	ABSENT		

ULTRA SOUND SCAN DETAILS

DATE OF ULTRASOUND *by ULTRASOUND SCAN*	12-08-2024		
METHOD FOR GESTATION AGE ESTIMATION *by ULTRASOUND SCAN*	ULTRASOUND SCAN DETAILS		
FOETUS (NOS) *by ULTRASOUND SCAN*	1		
GA ON THE DAY OF SAMPLE COLLECTION *by ULTRASOUND SCAN*	13.1	WEEKS	
CROWN RUMP LENGTH (CRL) *by ULTRASOUND SCAN*	72	mm	38 - 84
GESTATIONAL AGE BY CRL *by ULTRASOUND SCAN*	13.1		

DUAL MARKER - BIOCHEMICAL MARKERS

PREGNANCY ASSOCIATED PLASMA PROTEIN A (PAPP-A) *by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)*	10.1	mIU/L	
BETA HCG - FREE: SERUM *by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)*	56.1	ng/mL	

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Mrs. ANJALI**		
AGE/ GENDER	: 35 YRS/FEMALE	**PATIENT ID**	: 1578008
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408120032**
REFERRED BY	:	**REGISTRATION DATE**	: 12/Aug/2024 11:44 AM
BARCODE NO.	: 01514938	**COLLECTION DATE**	: 12/Aug/2024 11:46AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 14/Aug/2024 04:18PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
MULTIPLE OF MEDIAN (MOM) VALUES			
PAPP-A MOM *by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)*	1.31		
BETA HCG - FREE MOM *by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)*	1.82		
TRISOMY 21 SCREENING (DOWNS SYNDROME) RISK ASSESSMENT			
TRISOMY 21 SCREENING RISK RESULT ***by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)***	**POSITIVE (+ve)**		**NEGATIVE (-ve)**
TRISOMY 21 AGE RISK *by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)*	1:280		
TRISOMY 21 BIOCHEMICAL RISK *by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)*	1:2900		RISK CUT OFF 1:200
TRISOMY 21 COMBINED RISK (BIOCHEMICAL + NT) *by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)*	>1:50		RISK CUT OFF 1:200
TRISOMY 18 SCREENING RISK ASSESSMENT			
TRISOMY 18 AGE RISK *by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)*	NEGATIVE (-ve)		
TRISOMY 13/18 SCREENING RISK *by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)*	1:2625 NEGATIVE (-ve)		RISK CUT OFF 1:300

INTERPRETATION:

1.Double marker test (maternal serum screen – first trimester) is a prenatal test to screen for Trisomy 21 (down's syndrome) and Trisomy 13/18 during gestational period 8 – 13 weeks.
2.Besides the biochemical markers tested – maternal pregnancy associated plasma protein a (papp-a) & maternal free beta hcg , the risk is calculated combining usg measurement of nuchat translucency (nt), gestational age at the time of sample with other maternal factors as age, weight, h/o diabetes, smoking, race, twin pregnancies, use of assissted reproductive technologies (IVF).

NOTE:

1.This is only screening test based purely on statistical analysis which is further based on the data submitted; hence the correctness of data is vital for risk analysis.
2.A negative screen indicates a lower probability of having a baby with trisomy 21 ,trisomy 18 and neural tube defects, but does not completely exclude the possibility.
3.A positive screen on the contrary only indicates a higher probability of having a baby with trisomy 21, trisomy 18 and neural tube defects, and needs confirmation by cytogenetic studies and/or level ii scan.
4.The detection rate by this test is about 60%, with 5% false positive rate when assesment is done for only biochemical parameters and increase to 85 % with 5% false positive rate when both biochemical parameters and nt are combined for analysis.
5.Correlation with patient history, family history and detailed USG scan is required to decide further course of action in cases who have high risk statistically calculated by this test.

TRISOMY 21 (DOWN SYNDROME) RISK ASSESSMENT :SCREEN IS POSITIVE. THE CALCULATED RISK FOR

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Mrs. ANJALI**		
AGE/ GENDER	: 35 YRS/FEMALE	**PATIENT ID**	: 1578008
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012408120032**
REFERRED BY	:	**REGISTRATION DATE**	: 12/Aug/2024 11:44 AM
BARCODE NO.	: 01514938	**COLLECTION DATE**	: 12/Aug/2024 11:46AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 14/Aug/2024 04:18PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

TRISOMY 21(WITH NUCHAL TRANSLUCENCY) IS ABOVE THE CUT OFF, WHICH INDICATES A HIGH RISK.

NOTE: Please Correlate Clinically and Repeat Test after 16 Weeks as Triple or Quadruple Marker with Current USG copy.

SAMPLE WAS ALSO OUTSOURCED TO IMMUNODIAGNOSTIC PVT.LTD FOR RECHECK CONFIRMATION AND EVALUATION. ORIGINAL GRAPH ATTACHED

*** End Of Report ***

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Immunodiagnostics Pvt.Ltd.,
109, Pocket D&E, Local Shopping Complex,109, Pocket D&E, Local Shopping Complex,
Sarita Vihar

Prisca 5.2.0.13

Date of report: 14/08/2024

KOS DIAG LAB

Patient data

Name	MRS. ANJALI	Patient ID	
Birthday	22/08/1989	Sample ID	2408220459/AMB
Age at sample date	35.0	Sample Date	12/08/2024
Gestational age	13 + 1		

Correction factors

Fetuses	1	IVF	no	Previous trisomy 21 pregnancies	no
Weight	56.3	diabetes	no		
Smoker	no	Origin	Asian		

Biochemical data

Parameter	Value	Corr. MoM
PAPP-A	10.1 mIU/ml	1.82
fb-hCG	56.1 ng/ml	1.31

Risks at sampling date

Age risk	1:280
Biochemical T21 risk	1:2900
Combined trisomy 21 risk	>1:50
Trisomy 13/18 + NT	1:2625

Ultrasound data

Gestational age	13 + 1
Method	CRL Robinson
Scan date	12/08/2024
Crown rump length in mm	72
Nuchal translucency MoM	2.45
Nasal bone	absent
Sonographer	DR. RAJEEV GUPTA
Qualifications in measuring NT	M.D



Trisomy 21

The calculated risk for Trisomy 21 (with nuchal translucency) is above the cut off, which indicates an increased risk.

After the result of the Trisomy 21 Test (with nuchal translucency), it is expected that among less than 50 pregnancies with the same data, there is one trisomy 21 pregnancy.

The calculated risk by PRISCA depends on the accuracy of the information provided by the referring physician.

Please note that risk calculations are statistical approaches and have no diagnostic value!

The patient combined risk presumes the NT measurement was done according to accepted guidelines (Prenat Diagn 18: 511-523 (1998)).

The laboratory can not be hold responsible for their impact on the risk assessment ! Calculated risks have no diagnostic value!

Trisomy 13/18 + NT

The calculated risk for Trisomy 13/18 (with nuchal translucency) is 1:2625, which represents a low risk.

Sign of Physician

below cut off | Below Cut Off, but above Age Risk | above cut off